Prostate cancer: Sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy - Results of ACRIN prospective multi-institutional clinicopathologic study

Radiology

Volumn 251, Issue 1, 2009, Pages 122-133

  Weinreb, Jeffrey C ^a   Blume, Jeffrey D ^b   Coakley, Fergus V ^c   Wheeler, Thomas M ^d   Cormack, Jean B ^b   Sotto, Christopher K ^c   Cho, Haesun ^e   Kawashima, Akira ^f   Tempany Afdhal, Clare M ^g   Macura, Katarzyna J ^h   Rosen, Mark ⁱ   Gerst, Scott R ^j   Kurhanewicz, John ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f MAYO CLINIC   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CANCER LOCALIZATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARAMETER; PERIPHERAL ZONE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; RANK SUM TEST; RECEIVER OPERATING CHARACTERISTIC; RECTUM; SCORING SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; METHODOLOGY; MIDDLE AGED; PREOPERATIVE CARE; PROSTATE TUMOR; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; UNITED STATES;

AGED; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PREOPERATIVE CARE; PROSTATECTOMY; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 64949083536     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2511080409     Document Type: Article

References (46)

1. American Cancer Society. Cancer facts and figures 2007. Publication no. 500807. Atlanta, Ga: American Cancer Society, 2006.
2. Brown ML, Lipscomb J, Snyder C. The burden of illness of cancer: economic cost and quality of life. Annu Rev Public Health 2001;22:91-113. (Pubitemid 32452500)
3. Brown ML, Riley GF, Schussler N, Etzioni R. Estimated health care costs related to cancer treatment from SEER-Medicare data. Med Care 2002;40(8 suppl):IV-117.
4. Sakr WA, Grignon DJ. Prostate cancer: indicators of aggressiveness. Eur Urol 1997;32(suppl 3):15-23. (Pubitemid 27355060)
5. Obek C, Louis P, Civantos F, Soloway MS. Comparison of digital rectal examination and biopsy results with the radical prostatectomy specimen. J Urol 1999;161:494-498.
6. Mettlin CJ, Black B, Lee F, et al. Workgroup #2: screening and detection - reference range/clinical issues of PSA. Cancer 1993;71:2679-2680.
7. Salomon L, Colombel M, Patard JJ, et al. Value of ultrasound-guided systematic sextant biopsies in prostate tumor mapping. Eur Urol 1999;35:289-293.
8. Smith JA, Scardino PT, Resnick MI, et al. Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective multi-institutional trial. J Urol 1997;157:902-906.
9. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. JAMA 1997;277:1445-1451.
10. Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001;58:843-848.
11. Huch Boni RA, Boner JA, Debatin JF, et al. Optimization of prostate carcinoma staging: comparison of imaging and clinical methods. Clin Radiol 1995;50:593-600.
12. Yu KK, Hricak H, Alagappan R, et al. Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging: multivariate feature analysis. Radiology 1997;202:697-702.
13. Kurhanewicz J, Vigneron DB, Hricak H, et al. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology 1996;198:795-805.
14. Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging - clinicopathologic study. Radiology 1999;213:473-480.
15. Coakley FV, Kurhanewicz J, Lu Y, et al. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology 2002;223:91-97.
16. Thornbury JR, Ornstein DK, Choyke PL, Langlotz CP, Weinreb JC. Prostate cancer: what is the future role for imaging? AJR Am J Roentgenol 2001;176:17-22.
17. Yu KK, Scheidler J, Hricak H, et al. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 1999;213:481-488.
18. Kurhanewicz J, Vigneron DB, Hricak H, et al. Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. Radiology 1996;200:489-496.
19. Schricker AA, Pauly JM, Kurhanewicz J, Swanson MG, Vigneron DB. Dualband spectral-spatial RF pulses for prostate MR spectroscopic imaging. Magn Reson Med 2001;46:1079-1087. (Pubitemid 33104295)
20. Tran TK, Vigneron DB, Sailasuta N, et al. Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer. Magn Reson Med 2000;43:23-33.
21. Wheeler TM, Lebovitz RM. Fresh tissue harvest for research from prostatectomy specimens. Prostate 1994;25:274-279. (Pubitemid 24364132)
22. American Joint Committee on Cancer. Prostate. In: Greene FL, Page DL, Fleming ID, et al, eds. AJCC cancer staging manual. 6th ed. New York, NY: Springer, 2002; 309-316.
23. Jung JA, Coakley FV, Vigneron DB, et al. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology 2004;233:701-708.
24. Obuchowski NA. Nonparametric analysis of clustered ROC curve data. Biometrics 1997;53:567-578. (Pubitemid 27262219)
25. Obuchowski NA. Multireader, multimodality receiver operating characteristic curve studies: hypothesis testing and sample size estimation using an analysis of variance approach with dependent observations. Acad Radiol 1995;2(suppl 1):S22-S29.
26. Obuchowski NA. Computing sample size for receiver operating characteristic studies. Invest Radiol 1994;29:238-243. (Pubitemid 24099855)
27. Obuchowski NA, McClish DK. Sample size determination for diagnostic accuracy studies involving binormal ROC curve indices. Stat Med 1997;16:1529-1542. (Pubitemid 27322656)
28. Obuchowski NA. Sample size calculations in studies of test accuracy. Stat Methods Med Res 1998;7:371-392. (Pubitemid 28559255)
29. Sadek AG, Mitchell DG, Siegelman ES, Outwater EK, Matteucci T, Hann HW. Early hepatocellular carcinoma that develops within macroregenerative nodules: growth rate depicted at serial MR imaging. Radiology 1995;195:753-756.
30. Hom JJ, Coakley FV, Simko JP, et al. Prostate cancer: endorectal MR imaging and MR spectroscopic imaging - distinction of true-positive results from chance-detected lesions. Radiology 2006;238:192-199.
31. Futterer JJ, Heijmink SW, Scheenen TW, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006;241:449-458.
32. Westphalen AC, Coakley FV, Qayyum A, et al. Peripheral zone prostate cancer: accuracy of different interpretative approaches with MR and MR spectroscopic imaging. Radiology 2008;246:177-184.
33. Testa C, Schiavina R, Lodi R, et al. Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. Radiology 2007;244:797-806.
34. Rifkin MD, Zerhouni EA, Gatsonis CA, et al. Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer: results of a multi-institutional cooperative trial. N Engl J Med 1990;323:621-626.
35. Tempany CM, Zhou X, Zerhouni EA, et al. Staging of prostate cancer: results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques. Radiology 1994;192:47-54.
36. D'Amico AV, Whittington R, Malkowicz B, et al. Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer. J Urol 2000;164(3 pt 1):759-763.
37. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003;95:981-989. (Pubitemid 36896715)
38. Freedland SJ, Partin AW, Humphreys EB, Mangold LA, Walsh PC. Radical prostatectomy for clinical stage T3a disease. Cancer 2007;109:1273-1278. (Pubitemid 46466553)
39. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999;281:1395-1400. (Pubitemid 29190217)
40. Carroll PR, Presti JC Jr, Small E, Roach M 3rd. Focal therapy for prostate cancer 1996: maximizing outcome. Urology 1997;49(3a suppl):84-94.
41. Li H, Sugimura K, Kaji Y, et al. Conventional MRI capabilities in the diagnosis of prostate cancer in the transition zone. AJR Am J Roentgenol 2006;186:729-742.
42. Zakian KL, Eberhardt S, Hricak H, et al. Transition zone prostate cancer: metabolic characteristics at 1H MR spectroscopic imaging - initial results. Radiology 2003;229:241-247.
43. Akin O, Sala E, Moskowitz CS, et al. Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology 2006;239:784-792.
44. Futterer JJ, Scheenen TW, Huisman HJ, et al. Initial experience of 3 tesla endorectal coil magnetic resonance imaging and 1H-spectroscopic imaging of the prostate. Invest Radiol 2004;39:671-680.
45. Futterer JJ, Engelbrecht MR, Huisman HJ, et al. Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology 2005;237:541-549.
46. Kozlowski P, Chang SD, Jones EC, et al. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis: correlation with biopsy and histopathology. J Magn Reson Imaging 2006;24:108-113.